VEEVNYSEServices-Prepackaged SoftwareUS GAAP · USD

Veeva Systems Inc

Veeva Systems is a U.S.-based software company focused on cloud applications, data products, and consulting services for the global life sciences industry. Its software supports pharmaceutical and biotechnology customers across research and development, quality, medical, and commercial operations, with offerings delivered primarily through the Veeva Vault platform and related cloud services.

Revenue3,195m USD
+16.3 %y/y
Operating profit (EBIT)916m USD
+32.5 %y/y
EBIT margin28.7%
+3.5 ppy/y
Net income909m USD
+27.3 %y/y
Free cash flow1,415m USD
+29.8 %y/y

Fiscal year 2026 · change from previous year

Development 2021–2026

01,0002,0003,0004,000m USD2021: 1,465 m USD2021: EBIT 378 m USD20212022: 1,851 m USD2022: EBIT 505 m USD20222023: 2,155 m USD2023: EBIT 459 m USD20232024: 2,364 m USD2024: EBIT 429 m USD20242025: 2,747 m USD2025: EBIT 691 m USD20252026: 3,195 m USD2026: EBIT 916 m USD20263,195916
RevenueOperating profit (EBIT)

Business

Share of revenue
Commercial Cloud42 %

CRM, content, analytics, and engagement tools for life sciences commercial teams.

R&D Solutions41 %

Development and quality applications used across clinical, regulatory, and quality workflows.

Data Cloud10 %

Reference, deep, and transaction data products used to support commercial and clinical operations.

Professional Services and Other7 %

Implementation, configuration, training, managed services, and consulting.

Products

Reported · share of revenue
44.6%39.4%10.1%FY2026100 %
  • Subscription Services Veeva Research and Development and Quality Solutions44.6 %
  • Subscription Services Veeva Commercial Cloud39.4 %
  • Professional Services Veeva Research and Development and Quality Solutions10.1 %
  • Professional Services Veeva Commercial Cloud5.9 %

Source: 10-K FY2026, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Veeva sells primarily to pharmaceutical and biotechnology companies that need specialized software for regulated workflows across the drug lifecycle. It also serves clinical research sites and, to a smaller extent, companies outside life sciences that use its development and quality applications. Customers buy Veeva to standardize processes, manage regulated content and data, and support commercial and R&D operations on a life-sciences-specific platform.

Commercial Solutions customers

Pharma and biotech companies buying CRM, medical, content, and analytics tools for commercialization and field engagement.

R&D Solutions customers

Life sciences companies using development and quality applications for clinical, regulatory, and quality workflows.

Pre-commercial biotech and smaller R&D companies

Earlier-stage customers adopting Veeva for development workflows before commercialization.

Clinical research sites

Sites using Veeva solutions that support clinical operations and related collaboration.

Non-life-science enterprise customers

Selected customers outside life sciences using development and quality applications for regulated processes.

Strategy

Veeva’s strategy centers on expanding its industry cloud footprint across the life sciences value chain, from R&D through commercialization. It emphasizes deepening customer adoption of its Vault platform, migrating customers to newer products such as Vault CRM, and extending its data and analytics offerings to increase workflow coverage and switching costs.

Broaden the Vault platform footprintMedium term

A unified platform increases customer stickiness and supports cross-sell across functions.

Expand data and analytics offeringsMedium term

Data products deepen workflow integration and create recurring usage across commercial and clinical operations.

Support customer migration to next-generation productsShort term

Migration from legacy systems helps preserve accounts and modernize the installed base.

Extend consulting and implementation supportShort term

Services help customers deploy complex regulated workflows and reinforce platform adoption.

Geography

Q2/2026

Veeva serves a global customer base, with subscription revenue concentrated in North America, Europe, and Asia Pacific. In the reported quarters, subscription services revenue was about 59-61% from North America, 27-28% from Europe, and 12-13% from other locations, primarily Asia Pacific. The geographic mix matters because the company’s life sciences customers operate globally, but demand and regulatory requirements vary by region.

North America60 %
Europe30 %
Asia Pacific8.3 %
Other countries (US filing)2.1 %

Share of the revenue the company reports by geography.

Risks

Veeva faces competition from large enterprise software vendors, life-sciences software specialists, and data/analytics providers, especially where customers can substitute broader platforms or legacy systems. Its business is also exposed to cybersecurity, privacy, product reliability, and regulatory-compliance risks because its software handles sensitive clinical, medical, and commercial data in highly regulated markets.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Cybersecurity and data privacy breaches1Competitive pressure from enterprise and life-sciences software vendors2Migration risk from legacy CRM to Vault CRM3Regulatory and AI compliance risk4Product defects or service disruptions5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Cybersecurity and data privacy breachesImpact: CriticalLikelihood: Medium

    The company stores and processes sensitive customer and healthcare-related data.

    Exposure: Cloud software and data products

  2. Competitive pressure from enterprise and life-sciences software vendorsImpact: HighLikelihood: Medium

    Customers can choose broader platforms or point solutions instead of Veeva modules.

    ExposureCommercial CloudDevelopment CloudQuality CloudData Cloud
  3. Migration risk from legacy CRM to Vault CRMImpact: HighLikelihood: Medium

    Transitioning customers to a new platform can create implementation friction and churn risk.

    Exposure: CRM installed base

  4. Regulatory and AI compliance riskImpact: HighLikelihood: Medium

    Life sciences software must adapt to evolving privacy, data, and AI rules across regions.

    Exposure: Global operations and product design

  5. Product defects or service disruptionsImpact: HighLikelihood: Medium

    Failures in regulated workflows can reduce demand and create liability exposure.

    Exposure: Cloud applications and managed services

Accounting

Judgemental items
Revenue recognition and standalone selling price

Multi-element contracts require allocation across distinct performance obligations.

Impact: Can shift revenue timing between subscription, data, and services

Seasonality of subscription billings

The first fiscal quarter is seasonally strongest for cash inflows from annual billings.

Impact: Quarterly cash flow and working capital can be uneven

Professional services and consulting revenue

Implementation and consulting work may be recognized over time or as delivered.

Impact: Affects mix, margin profile, and quarterly revenue cadence

Stock-based compensation and RSU tax settlements

Equity awards and related tax payments influence financing cash flows.

Impact: Can create volatility in cash flow presentation

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

Veeva Systems Inc (VEEV) Revenue, Earnings & Financials 2026 – Clarifo